CAS: 52757-95-6; Sevelamer

该化合物是一种聚合化合物,主要用于对正在透析的慢性肾病患者的磷酸盐粘合剂,被归类为非吸收的,用阴离子交换的树脂,它通过在胃肠道中结合食用磷酸盐,有效减少磷酸盐的血清含量,防止其吸收.Sivelamer因其能够降低胆固醇水平,改进代谢参数,而除了其主要功能外,还具有其他能力.该物质通常以盐酸盐或碳酸盐的形式施用,这可以影响其溶性与稳定性.它一般被很好地调用,胃肠侧效应最为常见,包括恶心和内溶.Sivelamer不含有钙或铝,因此它对于面临超热性贫血或铝毒性风险的病人来说是一个更安全的替代方法.它的行动机制,连同其有利的安全特征,使它成为管理肾脏病人高磷酸盐的有价值的治疗选择.

结构式图片

MSDS等安全信息

    合成工艺路线路线简述

      📜盐酸司维拉姆,Sodium Hydroxide 反应 1.0H,反应生成 司维拉姆
      参考文献:Process For Preparation Of Sevelamer Carbonate
      标题:Process For Preparation Of Sevelamer Carbonate
      摘要:本发明公开了一种简单的制备聚烯丙胺聚合物盐的过程.

      海关参考信息

      专利信息


      专利号:US-2017283878-A1
      优先权日:2015-12-11
      标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
      发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
      权利人:ACADEMIA SINICA
      摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

      专利号:EP-1616964-B1
      优先权日:2004-06-30
      标 题 :Process for preparative in vitro protein biosynthesis
      发明人:STREY JAN DR; MERK HELMUT DR; STIEGE WOLFGANG DR
      权利人:QIAGEN GMBH
      摘要:Preparative in vitro synthesis of an expression product (I) in a cell-free transcription and translation system (A). Preparative in vitro synthesis of an expression product (I) in a cell-free transcription and translation system (A) comprises: (A) filling a reaction vessel with a solution containing components of (A) for a selected (I), amino acids and metabolic components that provide energy and are required for synthesis of (I); (B) performing synthesis of (I) for a predetermined time (T), without separation of substances formed and without addition of consumed synthesis substrates; (C) after expiry of T, low molecular weight metabolic products and/or reaction inhibitors are removed from solution; (D) immediately before, after or during step (c), the synthesis components that have been consumed are replaced; and (E) steps (b)-(d) are repeated, at least once, and in the last cycle, steps (c) and (d) may be omitted. An independent claim is also included for a similar method in which the reaction vessel may also include a system (A') for synthesis of a second, different product (I'), plus amino acids and required metabolic components; step (b) is as above; step (c) is omitted and step (d) is similar but includes addition of (A'), if not already present, and the final step is synthesis of (I') for a predetermined time, with separation of substances formed or addition of consumed synthesis substrates.

      专利号:CN-108434151-A
      优先权日:2008-01-11
      标题 :Synthesis of triterpenoids and method for treating diseases

      专利号:CN-102675510-A
      优先权日:2012-05-28
      标 题 :Synthesis of Sevelamer

      专利号:CN-104739841-B
      优先权日:2008-01-11
      标题:Synthesis of triterpenoids and method for treating diseases

      专利号:US-2007148246-A1
      优先权日:2005-08-11
      标题:Nucleic Acid-Based Matrixes
      发明人:LUO DAN; LI YOUGEN
      权利人:LUO DAN; LI YOUGEN
      摘要:Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include delivery of biologically active agents, cell and tissue culture, and cell-free protein synthesis.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知